Printer Friendly

TELOR OPHTHALMIC PHARMACEUTICALS, INC. RECEIVES CLEARANCE IN UK TO BEGIN PHASE III TRIALS FOR DRUG TO PREVENT EYE SURGERY COMPLICATION

 WOBURN, Mass., Aug. 10 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. (NASDAQ-NMS: TELR) today announced that the Medicines Control Agency of the U.K. Department of Health has cleared the company's Clinical Trial Exemption (CTX) application to allow Telor to begin Phase III trials for XARANO(TM) in the United Kingdom. XARANO is Telor's product under development for controlling acute increases in intraocular pressure in patients following cataract surgery.
 "Initiation of the clinical trials and associated regulatory activities for XARANO in the United Kingdom is the first step in our strategy to establish a presence and create an asset in the European market," commented Stephen J. Riggi, Ph.D., president and chief executive officer of Telor. "We are moving forward with the clinical development of XARANO based on encouraging results of our Phase I/II clinical trial."
 The trial in the U.K. is part of Telor's pivotal Phase III clinical evaluation program for XARANO which includes approximately 20 clinical centers at sites in the United States, Canada, Europe and Israel. In April 1993, Telor began multicenter Phase III studies in the United States.
 Each year, approximately 1.5 million cataract surgeries are performed in the United States. Despite current treatment, approximately 35-50 percent of patients experience transient post-operative rises in intraocular pressure ("IOP spike"). The incidence is higher in patients who have open-angle glaucoma or ocular hypertension, conditions associated with chronically elevated intraocular pressure. The IOP spike results from an increased resistance to fluid outflow through the trabecular meshwork of the eye. Acute increases in intraocular pressure can cause patient discomfort, wound site damage and loss of visual field.
 XARANO, a formulation of ethacrynic acid, is to be administered at the time of cataract surgery by the ophthalmic surgeon to prevent or reduce IOP spike by promoting the outflow of fluid from the eye. Current treatments used for the IOP spike which reduce fluid flow into the eye do not address the underlying cause of the condition.
 Telor has an exclusive worldwide license from the Massachusetts Eye and Ear Infirmary to patents issued in the United States, Canada, Australia and Europe and pending elsewhere covering the pharmaceutical use of ethacrynic acid to lower intraocular pressure by increasing the outflow of fluid from the eye.
 Telor is an ophthalmic pharmaceutical company dedicated to the development and marketing of innovative prescription pharmaceuticals for use in the treatment of age-related eye diseases and in ophthalmic surgery. The company's goal is to introduce into the worldwide ophthalmic pharmaceuticals market a broad portfolio of patent-protected products that are based on novel mechanisms of action and that offer significant improvements over existing therapies.
 The company's lead products in clinical development are TEKRON(TM), a potential product for topical use in controlling chronic elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension, and XARANO, a potential product for use during cataract surgery to prevent or reduce transient post-operative increases in intraocular pressure. In addition, clinical studies are underway to assess the feasibility of a pharmaceutical approach to the treatment of presbyopia, an age-related impairment of the ability of the eye to focus on near objects. Telor has its headquarters in Woburn, Mass.
 -0- 8/9/93
 /CONTACT: Stephen J. Riggi, Ph.D., president and chief executive officer, Telor Ophthalmic Pharmaceuticals, Inc., 617-937-0393; Lynne H. Brum of Feinstein Partners Inc., 617-577-8110, for Telor/
 (TELR)


CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU:

JL -- NE012 -- 1059 08/10/93 09:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993
Words:575
Previous Article:IMAGERY AND WORDPERFECT CORPORATION DELIVER ADVANCED DOCUMENT IMAGING CAPABILITIES TO WORDPERFECT OFFICE USERS
Next Article:DYNAMIC OIL STARTS DRILLING ON CONTINENT'S LAST DEEP RIVER BASIN
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters